Xenon Pharmaceuticals Inc.
XENE
Classifica tra le azioni
#4469
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Prezzo delle azioni
$36.38
Capitalizzazione di mercato
$3.52B
Variazione (1 giorno)
3.72%
Variazione (1 anno)
-16.24%
Paese
CA
Scambia Xenon Pharmaceuticals Inc. (XENE)
Categoria
Healthcare
Numero di azioni in circolazione per Xenon Pharmaceuticals Inc. (XENE)
Numero di azioni in circolazione al June 2026: 99.61M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Xenon Pharmaceuticals Inc., il numero attuale di azioni in circolazione è 99.61M. Alla fine del December 2023, la società aveva 66.89M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Xenon Pharmaceuticals Inc. (XENE) dal 2011 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno | Azioni in circolazione | Cambia |
|---|---|---|
| 2026 (TTM) | 99.61M | 27.88% |
| 2024 | 77.89M | 16.45% |
| 2023 | 66.89M | 10.48% |
| 2022 | 60.54M | 38.77% |
| 2021 | 43.63M | 26.30% |
| 2020 | 34.54M | 33.17% |
| 2019 | 25.94M | 33.53% |
| 2018 | 19.43M | 8.01% |
| 2017 | 17.99M | 16.08% |
| 2016 | 15.49M | 8.48% |
| 2015 | 14.28M | 2.89% |
| 2014 | 13.88M | 52.78% |
| 2013 | 9.09M | 582.58% |
| 2012 | 1.33M | 0.14% |
| 2011 | 1.33M | 0.00% |
Azioni in circolazione per aziende simili o concorrenti
| Azienda | Azioni in circolazione | Differenza | Il paese |
|---|---|---|---|
| 253.90M | 154.89% |
US
|
|
| 396.00M | 297.55% |
US
|
|
| 478.91M | 380.79% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -37.57% |
NL
|
